Identifying Barriers and Strategies to Support Self-efficacy for Medication Adherence With Text Messaging
![]() |
The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been evaluated by the U.S. Federal Government. Know the risks and potential benefits of clinical studies and talk to your health care provider before participating. Read our disclaimer for details. |
ClinicalTrials.gov Identifier: NCT02785848 |
Recruitment Status :
Recruiting
First Posted : May 30, 2016
Last Update Posted : July 7, 2020
|
- Study Details
- Tabular View
- No Results Posted
- Disclaimer
- How to Read a Study Record
Condition or disease | Intervention/treatment |
---|---|
Sickle Cell Disease | Other: Interviews and Surveys |
Study Type : | Observational |
Estimated Enrollment : | 50 participants |
Observational Model: | Cohort |
Time Perspective: | Prospective |
Official Title: | Identifying Patient-centered Barriers and Preferred Strategies to Support Self-efficacy for Medication Adherence With Two-way Text Messaging |
Study Start Date : | May 2016 |
Estimated Primary Completion Date : | May 2022 |
Estimated Study Completion Date : | May 2022 |

Group/Cohort | Intervention/treatment |
---|---|
Asthma and/or Sickle Cell Anemia
The investigators will examine patients with sickle cell disease, asthma, or both who are aged 12-70 years who take daily medications.
|
Other: Interviews and Surveys
The investigators will perform semi-structured interviews and surveys on this cohort |
- Number of patients with barriers to medication adherence [ Time Frame: 1 year ]High cost, forgetting, side effects, access to medications
- Number of patients that prefer a tailored text messaging technological solution [ Time Frame: 1 year ]

Choosing to participate in a study is an important personal decision. Talk with your doctor and family members or friends about deciding to join a study. To learn more about this study, you or your doctor may contact the study research staff using the contacts provided below. For general information, Learn About Clinical Studies.
Ages Eligible for Study: | 12 Years to 70 Years (Child, Adult, Older Adult) |
Sexes Eligible for Study: | All |
Accepts Healthy Volunteers: | No |
Sampling Method: | Non-Probability Sample |
Inclusion Criteria:
- Receiving care at the VUMC/Matthew Walker clinic
- Diagnosed with SCD, asthma, or both
- Currently taking daily medications for SCD, such as hydroxyurea, asthma, or both
- Having access to a mobile telephone and/or computer
- Age 12-70 years
Exclusion Criteria:
1. Unable to perform interviews or surveys

To learn more about this study, you or your doctor may contact the study research staff using the contact information provided by the sponsor.
Please refer to this study by its ClinicalTrials.gov identifier (NCT number): NCT02785848
Contact: Robert Cronin, MD, MS | 6159365097 | robert.cronin@vanderbilt.edu |
United States, Tennessee | |
Vanderbilt University | Recruiting |
Nashville, Tennessee, United States, 37203 | |
Contact: Robert Cronin, MD, MS 615-936-5097 robert.cronin@vanderbilt.edu | |
Contact: Michael DeBaun, MD, MPH (615) 875-3040 m.debaun@vanderbilt.edu |
Principal Investigator: | Robert Cronin, MD, MS | Vanderbilt University |
Responsible Party: | Robert Cronin, Assistant Professor, Vanderbilt University |
ClinicalTrials.gov Identifier: | NCT02785848 |
Other Study ID Numbers: |
160750 |
First Posted: | May 30, 2016 Key Record Dates |
Last Update Posted: | July 7, 2020 |
Last Verified: | July 2020 |
Anemia, Sickle Cell Anemia, Hemolytic, Congenital Anemia, Hemolytic Anemia |
Hematologic Diseases Hemoglobinopathies Genetic Diseases, Inborn |